Identification of novel epitopes from human papillomavirus type 18 E7 that can sensitize PBMCs of multiple HLA class I against human cervical cancer

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Kim, Sunghoon ^a   Chung, Hye Won ^b   Lee, Kyoung Ryul ^c   Lim, Jong Baeck ^a  

^a Yonsei University College of Medicine   (South Korea)

^b International St Mary's Hospital   (South Korea)

^c Seoul Medical Science Institute   (South Korea)

Author keywords

Cervical cancer; Epitopes; HLA class I; HPV18 E7; Immunotherapy

Indexed keywords

ALANYLPHENYLALANYLGLUTAMINYLGLUTAMINYLLEUCYLPHENYLALANYLLEUCYLASPARAGYLTHREONYLLEUCYLSERYLPHENYLALANYLVALYLCYSTEINYLPROLINE; ARGINYLALANYLGLUTAMYLPROLYLGLUTAMINYLARGINYLHISTIDYLTHREONYLMETHIONYLLEUCYLCYSTEINYLMETHIONYLCYSTEINYLCYSTEINYLLYSINE; ASPARAGYLHISTIDYLGLUTAMINYLHISTIDYLLEUCYLPROLYLALANYLARGINYLARGINYLALANYLGLUTAMYLPROLYLGLUTAMINYLARGINYLHISTIDINE; ASPARTYLASPARTYLLEUCYLARGINYLPHENYLALANYLGLUTAMINYLGLUTAMINYLLEUCYLPHENYLALANYLLEUCYLASPARAGYLTHREONYLLEUCYLSERINE; ASPARTYLSERYLGLUTAMYLGLUTAMYLGLUTAMYLASPARAGYLASPARTYLGLUTAMYLISOLEUCYLASPARTYLGLYCYLVALYLASPARAGYLHISTIDYLGLUTAMINE; CD8 ANTIGEN; CYSTEINYLCYSTEINYLLYSYLCYSTEINYLGLUTAMYLALANYLARGINYLISOLEUCYLLYSYLLEUCYLVALYLVALYLGLUTAMYLSERYLSERINE; EPITOPE; GAMMA INTERFERON; GLUTAMINYLARGINYLHISTIDYLTHREONYLMETHIONYLLEUCYLCYSTEINYLMETHIONYLCYSTEINYLCYSTEINYLLYSLCYSTEINYLGLUTAMYLALANYLARGININE; GLUTAMINYLASPARTYLISOLEUCYLVALYLLEUCYLHISTIDYLLEUCYLGLUTAMYLPROLYLGLUTAMINYLASPARAGYLGLUTAMYLISOLEUCYLPROLYLVALINE; GLUTAMYLALANYLARGINYLISOLEUCYLLYSYLLEUCYLVALYLVALYLGLUTAMYLSERYLSERYLALANYLASPARTYLASPARTYLLYSINE; GLUTAMYLASPARAGYLASPARTYLGLUTAMYLISOLEUCYLASPARTYLGLYCYLVALYLASPARAGYLHISTIDYLGLUTAMINYLHISTIDYLLEUCYLPROLYLALANINEP; GLUTAMYLGLUTAMINYLLEUCYLSERYLASPARTYLSERYLGLUTAMYLGLUTAMYLGLUTAMYLASPARAGYLASPARTYLGLUTAMYLISOLEUCYLASPARTYLGLYCINE; GLUTAMYLSERYLSERYLALANYLASPARTYLASPARTYLLEUCYLARGINYLALANYLPHENYLALANYLGLUTAMINYLGLUTAMINYLLEUCYLPHENYLALANYLLYSINE; HLA ANTIGEN CLASS 1; ISOLEUCYLASPARTYLGLYCYLVALYLASPARAGYLHISTIDYLGLUTAMINYLHISTIDYLLEUCYLPROLYLALANYLARGINYLARGINYLALANYLGLUTAMIC ACID; ISOLEUCYLPROLYLVALYLASPARTYLLEUCYLLEUCYLCYSTEINYLHISTIDYLGLUTAMYLGLUTAMINYLLEUCYLSERYLASPARTYLSERYLGLUTAMIC ACID; LEUCYLHISTIDYLLEUCYLGLUTAMYLPROLYLGLUTAMINYLASPARAGYLGLUTAMYLISOLEUCYLPROLYLVALYLASPARTYLLEUCYLLEUCYLCYSTEINE; LEUCYLLEUCYLCYSTEINYLHISTIDYLGLUTAMYLGLUTAMINYLLEUCYLSERYLASPARTYLSERYLGLUTAMYLGLUTAMYLGLUTAMYLASPARAGYLASPARTIC ACID; LEUCYLPHENYLALANYLLEUCYLASPARAGYLTHREONYLLEUCYLSERYLPHENYLALANYLVALYLCYSTEINYLPROLYLTRYPTOPHANYLCYSTEINYLALANYLSERINE; LEUCYLPROLYLALANYLARGINYLARGINYLALANYLGLUTAMYLPROLYLGLUTAMINYLARGINYLHISTIDYLTHREONYLETHIONYLLEUCYLCYSTEINE; LYSYLALANYLTHREONYLLEUCYLGLUTAMINYLASPARTYLISOLEUCYLVALYLLEUCYLHISTIDYLLEUCYLGLUTAMYLPROLYLGLUTAMINYLASPARAGINE; LYSYLLEUCYLVALYLVALYLGLUTAMYLSERYLSERYLALANYLASPARTYLASPARTYLLEUCYLARGINYLALANYLPHENYLALANYLGLUTAMINE; METHIONYLHISTIDYLGLYCYLPROLYLLYSYLALANYLTHREONYLLEUCYLGLUTAMINYLASPARTYLISOLEUCYLVALYLLEUCYLHISTIDYLLEUCINE; METHIONYLLEUCYLCYSTEINYLMETHIONYLCYSTEINYLCYSTEINYLLYSYLCYSTEINYLGLUTAMYLALALNYLARGINYLISOLEUCYLLYSYLLYSYLLEUCYLVALINE; PEPTIDE; PROLYLGLUTAMINYLASPARAGYLGLUTAMYLISOLEUCYLPROLYLVALYLASPARTYLLEUCYLLEUCYLCYSTEINYLHISTIDYLGLUTAMYLGLUTAMINYLLEUCINE; PROTEIN E7; UNCLASSIFIED DRUG; UNINDEXED DRUG; CANCER VACCINE; DNA BINDING PROTEIN; E7 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18; ONCOPROTEIN;

ALLELE; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHROMIUM RELEASE ASSAY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 18; IN VITRO STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; UTERINE CERVIX CANCER; CHEMISTRY; CLASSIFICATION; EPITOPE MAPPING; IMMUNIZATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; LYMPHOCYTE ACTIVATION; MONONUCLEAR CELL; TH1 CELL; TUMOR CELL LINE; UTERINE CERVICAL NEOPLASMS;

AMINO ACID SEQUENCE; CANCER VACCINES; CELL LINE, TUMOR; DNA-BINDING PROTEINS; EPITOPE MAPPING; EPITOPES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNIZATION; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; ONCOGENE PROTEINS, VIRAL; TH1 CELLS; UTERINE CERVICAL NEOPLASMS;

EID: 84929940614     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-014-0229-7     Document Type: Article

References (26)

1. De Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M: Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012, 13:607-615.
2. Morrow MP, Yan J, Sardesai NY: Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer. Expert Rev Vaccines 2013, 12:271-283.
3. Pisani P, Bray F, Parkin DM: Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002, 97:72-81.
4. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
5. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, Liu L, Lynch CF, Wentzensen N, Jordan RC, Altekruse S, Anderson WF, Rosenberg PS, Gillison ML: Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011, 29:4294-4430.
6. Shiels MS, Pfeiffer RM, Chaturvedi AK, Kreimer AR, Engels EA: Impact of the HIV epidemic on the incidence rates of anal cancer in the United States. J Natl Cancer Inst 2012, 104:1591-1598.
7. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA, Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356:1928-1943.
8. Kim JJ: Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 2010, 10:845-852.
9. Muñoz N, Bosch FX, De Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ: International agency for research on cancer multicenter cervical cancer study group; epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527.
10. CDC press release: National survey shows HPV vaccine rates trail other teen vaccines. www.cdc.gov/media/releases/2011/p0825_hpv_vaccine.html.
11. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, Schiller JT, Gonzalez P, Dubin G, Porras C, Jimenez SE, Lowy DR: Costa Rican HPV vaccine trial group. Effect of human papillomavirus 16/18 L1 virus like particle vaccine among young women with preexisting infection. JAMA 2007, 298:743-753.
12. EMA: Annex I Summary of Product Characteristics for the HPV Vaccine 'Gardasil' 2008. Updated 2012. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000703/WC5000 21142.pdf.
13. Schorge JO, Molpus KL, Koelliker D, Nikui N, Goodman A, Fuller AF: Stage IB and IIA cervical cancer with negative lymph nodes: the role of adjuvant radiotherapy after radical hysterectomy. Gynecol Oncol 1997, 66:31-35.
14. Cannistra SA, Niloff JM: Cancer of the uterine cervix. N Engl J Med 1996, 334:1030-1038.
15. Ma B, Xu Y, Hung CF, Wu TC: HPV and therapeutic vaccines: where are we in 2010. Curr Can Ther Rev 2010, 6:81-103.
16. van der Burg SH, Melief MC: Therapeutic vaccination against human papilloma virus induced malignancies. Curr Opin Immuol 2011, 23:252-257.
17. Su JH, Wu A, Scotney E, Ma B, Monie A, Hung CF, Wu TC: Immunotherapy for cervical cancer research status and clinical potential. BioDrugs 2010, 24:109-129.
18. Lin K, Roosinovich E, Ma B, Hung CF, Wu TC: Therapeutic HPV DNA vaccines. Immunol Res 2010, 47:86-112.
19. Jang S, Kim YT, Chung HW, Lee KR, Lim JB, Lee K: Identification of novel immunogenic human leukocyte antigen-A 2402-binding epitopes of human papillomavirus type 16 E7 for immunotherapy against human cervical cancer. Cancer 2012, 118:2173-2183.
20. Yan J, Harris K, Khan AS, Draghia-Akli R, Sewell D, Weiner DB: Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques. Vaccine 2008, 26:5210-5215.
21. Cunha-Neto E: MHC-restricted antigen presentation and recognition: constraints on gene, recombinant and peptide vaccines in humans. Braz J Med Biol Res 1999, 32:199-205.
22. Rammensee HG: Chemistry of peptides associated with MHC class I and class II molecules. Curr Opin Immunol 1995, 7:85-96.
23. Rammensee HG, Friede T, Stevanoviic S: MHC ligands and peptide motifs: first listing. Immunogenetics 1995, 41:178-228.
24. Meister GE, Roberts CG, Berzofsky JA, De Groot AS: Two novel T-cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences. Vaccine 1995, 13:581-591.
25. Lim JB, Kim HO, Jeong SH, Ha JE, Jang S, Lee SG, Lee K, Stroncek D: Identification of HLA-A* 2402-restricted HCMV immediate early-1 (IE-1) epitopes as targets for CD8+ HCMV-specific cytotoxic T lymphocytes. J Transl Med 2009, 7:72-82.
26. Friedl F, Kimura I, Osato T, Ito Y: Studies on a new human cell line (SiHa) derived from carcinoma of uterus. I. Its establishment and morphology. Proc Soc Exp Biol Med 1970, 135:543-545.